Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Building bridges toward invasion: tumor promoter treatment induces a novel protein kinase C-dependent phenotype in MCF10A mammary cell acini.

Klos KS, Warmka JK, Drachenberg DM, Chang L, Luxton GW, Leung CT, Schwertfeger KL, Wattenberg EV.

PLoS One. 2014 Mar 5;9(3):e90722. doi: 10.1371/journal.pone.0090722. eCollection 2014.

2.

miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance.

Liu Z, Liu H, Desai S, Schmitt DC, Zhou M, Khong HT, Klos KS, McClellan S, Fodstad O, Tan M.

J Biol Chem. 2013 Feb 8;288(6):4334-45. doi: 10.1074/jbc.M112.419168. Epub 2012 Dec 19.

3.

Genotoxic exposure during juvenile growth of mammary gland depletes stem cell activity and inhibits Wnt signaling.

Klos KS, Kim S, Alexander CM.

PLoS One. 2012;7(11):e49902. doi: 10.1371/journal.pone.0049902. Epub 2012 Nov 21.

4.

Separating stem cells by flow cytometry: reducing variability for solid tissues.

Alexander CM, Puchalski J, Klos KS, Badders N, Ailles L, Kim CF, Dirks P, Smalley MJ.

Cell Stem Cell. 2009 Dec 4;5(6):579-83. doi: 10.1016/j.stem.2009.11.008.

5.

The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage.

Badders NM, Goel S, Clark RJ, Klos KS, Kim S, Bafico A, Lindvall C, Williams BO, Alexander CM.

PLoS One. 2009 Aug 12;4(8):e6594. doi: 10.1371/journal.pone.0006594.

6.

Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development.

McDermott SP, Ranheim EA, Leatherberry VS, Khwaja SS, Klos KS, Alexander CM.

Oncogene. 2007 Mar 1;26(10):1407-16. Epub 2006 Sep 4.

PMID:
16953225
7.
8.

ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.

Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D.

Cancer Res. 2005 Mar 1;65(5):1858-67.

9.

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.

Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D.

Clin Cancer Res. 2004 Oct 15;10(20):6779-88.

10.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D.

Cancer Cell. 2004 Aug;6(2):117-27.

11.

Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer.

Klos KS, Yu D.

Cancer Biol Ther. 2004 Feb;3(2):205-6. Epub 2004 Feb 1. No abstract available.

PMID:
14764991

Supplemental Content

Support Center